M Bajo1, S E Montgomery1, L N Cates2, T Nadav2, A M Delucchi1, K Cheng3, H Yin3, E F Crawford1, A J Roberts2, M Roberto4. 1. Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA 92037, USA. 2. Molecular and Cellular Neuroscience, The Scripps Research Institute, La Jolla, CA 92037, USA. 3. Department of Chemistry and Biochemistry, BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80309, USA. 4. Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA 92037, USA mroberto@scripps.edu.
Abstract
AIMS: Several lines of evidence support a critical role of TLR4 in the neuroimmune responses associated with alcohol disorders and propose inhibitors of TLR4 signaling as potential treatments for alcoholism. In this work, we investigated the effect of T5342126 compound, a selective TLR4 inhibitor, on excessive drinking and microglial activation associated with ethanol dependence. METHODS: We used 2BC-CIE (two-bottle choice-chronic ethanol intermittent vapor exposure) paradigm to induce ethanol dependence in mice. After induction of the ethanol dependence, we injected T5342126 (i.p., 57 mg/kg) for 14 days while monitoring ethanol intake by 2BC (limited access to ethanol) method. RESULTS: T5342126 decreased ethanol drinking in both ethanol-dependent and non-dependent mice but T5342126 showed also dose-dependent non-specific effects represented by decreased animal locomotor activity, saccharine intake, and body core temperature. Six days after the last ethanol-drinking session, we examined the immunohistochemical staining of Iba-1 (ionized calcium-binding adapter molecule 1), a microglial activation marker, in the central nucleus of the amygdala (CeA) and dentate gyrus (DG) of the hippocampus. Notably, T5342126 reduced Iba-1 density in the CeA of both ethanol-dependent and non-dependent mice injected with T5342126. There were no significant differences in the DG Iba-1 density among the treatment groups. CONCLUSIONS: Collectively, our data suggest that T5342126, via blocking TLR4 activation, contributes to the reduction of ethanol drinking and ethanol-induced neuroimmune responses. However, the non-specific effects of T5342126 may play a significant role in the T5342126 effects on ethanol drinking and thus, may limit its therapeutic potential for treatment of alcohol dependence. SHORT SUMMARY: T5342126, an experimental TLR4 inhibitor, is effective in reducing ethanol drinking and inhibiting the activation and proliferation of microglia in both ethanol-dependent and non-dependent mice. However, T5342126's use as a potential candidate for the treatment of alcohol addiction may be limited due to its non-specific effects.
AIMS: Several lines of evidence support a critical role of TLR4 in the neuroimmune responses associated with alcohol disorders and propose inhibitors of TLR4 signaling as potential treatments for alcoholism. In this work, we investigated the effect of T5342126 compound, a selective TLR4 inhibitor, on excessive drinking and microglial activation associated with ethanol dependence. METHODS: We used 2BC-CIE (two-bottle choice-chronic ethanol intermittent vapor exposure) paradigm to induce ethanol dependence in mice. After induction of the ethanol dependence, we injected T5342126 (i.p., 57 mg/kg) for 14 days while monitoring ethanol intake by 2BC (limited access to ethanol) method. RESULTS:T5342126 decreased ethanol drinking in both ethanol-dependent and non-dependent mice but T5342126 showed also dose-dependent non-specific effects represented by decreased animal locomotor activity, saccharine intake, and body core temperature. Six days after the last ethanol-drinking session, we examined the immunohistochemical staining of Iba-1 (ionized calcium-binding adapter molecule 1), a microglial activation marker, in the central nucleus of the amygdala (CeA) and dentate gyrus (DG) of the hippocampus. Notably, T5342126 reduced Iba-1 density in the CeA of both ethanol-dependent and non-dependent mice injected with T5342126. There were no significant differences in the DG Iba-1 density among the treatment groups. CONCLUSIONS: Collectively, our data suggest that T5342126, via blocking TLR4 activation, contributes to the reduction of ethanol drinking and ethanol-induced neuroimmune responses. However, the non-specific effects of T5342126 may play a significant role in the T5342126 effects on ethanol drinking and thus, may limit its therapeutic potential for treatment of alcohol dependence. SHORT SUMMARY:T5342126, an experimental TLR4 inhibitor, is effective in reducing ethanol drinking and inhibiting the activation and proliferation of microglia in both ethanol-dependent and non-dependent mice. However, T5342126's use as a potential candidate for the treatment of alcohol addiction may be limited due to its non-specific effects.
Authors: Yue Wu; Erin L Lousberg; Lachlan M Moldenhauer; John D Hayball; Sarah A Robertson; Janet K Coller; Linda R Watkins; Andrew A Somogyi; Mark R Hutchinson Journal: Brain Behav Immun Date: 2011-01-27 Impact factor: 7.217
Authors: Yue Wu; Erin L Lousberg; Lachlan M Moldenhauer; John D Hayball; Janet K Coller; Kenner C Rice; Linda R Watkins; Andrew A Somogyi; Mark R Hutchinson Journal: Br J Pharmacol Date: 2012-03 Impact factor: 8.739
Authors: Douglas E Bevan; Alexander J Martinko; Lisa C Loram; Joshua A Stahl; Frederick R Taylor; Sampada Joshee; Linda R Watkins; Hang Yin Journal: ACS Med Chem Lett Date: 2010-04-12 Impact factor: 4.345
Authors: Richard L Bell; Marcelo F Lopez; Changhai Cui; Mark Egli; Kirk W Johnson; Kelle M Franklin; Howard C Becker Journal: Addict Biol Date: 2013-11-11 Impact factor: 4.280
Authors: R Adron Harris; Michal Bajo; Richard L Bell; Yuri A Blednov; Florence P Varodayan; Jay M Truitt; Giordano de Guglielmo; Amy W Lasek; Marian L Logrip; Leandro F Vendruscolo; Amanda J Roberts; Edward Roberts; Olivier George; Jody Mayfield; Timothy R Billiar; David J Hackam; R Dayne Mayfield; George F Koob; Marisa Roberto; Gregg E Homanics Journal: J Neurosci Date: 2016-12-16 Impact factor: 6.167
Authors: Scott P Goulding; Giordano de Guglielmo; Lieselot L G Carrette; Olivier George; Candice Contet Journal: Alcohol Clin Exp Res Date: 2019-08-30 Impact factor: 3.455
Authors: Reesha R Patel; Sophia Khom; Michael Q Steinman; Florence P Varodayan; William B Kiosses; David M Hedges; Roman Vlkolinsky; Tali Nadav; Ilham Polis; Michal Bajo; Amanda J Roberts; Marisa Roberto Journal: Brain Behav Immun Date: 2018-10-26 Impact factor: 7.217
Authors: Jonathan Henry W Jacobsen; Femke T A Buisman-Pijlman; Sanam Mustafa; Kenner C Rice; Mark R Hutchinson Journal: Brain Behav Immun Date: 2017-08-30 Impact factor: 7.217